Intravenous Artesunate for the Treatment of Severe Malaria

@article{Hess2010IntravenousAF,
  title={Intravenous Artesunate for the Treatment of Severe Malaria},
  author={Karl M. Hess and Jeffery A. Goad and Paul M. Arguin},
  journal={Annals of Pharmacotherapy},
  year={2010},
  volume={44},
  pages={1250 - 1258}
}
Objective: To review the pharmacodynamics and pharmacotherapeutic use of intravenous artesunate for the treatment of severe malaria. Data Sources: Literature was retrieved through PubMed (1999–March 2010), MEDLINE (1996–March 2010), and the Centers for Disease Control and Prevention (CDC), using the search terms artemisinin, artesunate, malaria, and severe malaria. In addition, reference citations from publications identified were reviewed. Study Selection and Data Extraction: All articles in… Expand
Artesunate to treat severe malaria in travellers: review of efficacy and safety and practical implications
TLDR
The frequency of PADH supports the need of weekly follow-up of haematological parameters during 1 month and full GMP qualification for the drug and rapid approval by drug agencies is warranted, backed by clear recommendations for optimal use. Expand
Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults
TLDR
Plasma concentrations of artesunate and dihydroartemisinin were achieved rapidly with rapid and complete symptom resolution and parasite clearance with no adverse events. Expand
An evaluation of rectal artesunate for the pre-hospital management of severe malaria
  • B. Angus
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2020
TLDR
Rectal artesunate (RAS) has been developed for use in the WHO approved strategy of pre-referral intervention and is a very useful, potentially lifesaving formulation designed to be quickly administered in remote areas to severely unwell children by non-medical personnel. Expand
Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study
TLDR
Intravenous AS can provide much higher peak concentrations of AS when compared to concentrations achieved with oral therapy; this may be crucial for the rapid elimination of parasites in patients with severe malaria. Expand
Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre
TLDR
IV AS is found to be safe and effective, with shorter LOS, faster parasite and fever clearance, no fatalities or hypoglycaemic events, and fewer ICU admissions versus IV Q, corroborates both developing world trials and smaller European case series. Expand
Treatment of imported severe malaria with artesunate instead of quinine - more evidence needed?
TLDR
The implications of existing evidence for the treatment of imported severe malaria are discussed and current evidence shows that intravenous artesunate is more effective than quinine in treating severe malaria in endemic countries. Expand
Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration
TLDR
There is evidence suggesting that the pharmacokinetics of AS and/or DHA following AS administration may be altered by pregnancy and by acute malaria infection, but further investigation would be required to define those alterations precisely. Expand
Availability and prescription practice of anti-malaria drugs in the private health sector in Yemen.
TLDR
Adherence of clinicians in the private sector to the new national guidelines for anti-malaria drugs improved from 21% in pre-intervention period to 38% after the intervention for artesunate + SP being prescribed as the first-line treatment. Expand
Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study
TLDR
The safety of injectable AS, even at the highest dose of 8 mg/kg increases the probability of therapeutic success of the drug even in patients with large variability of parasitaemia. Expand
Availability and prescription practice of anti-malaria drugs in the private health sector in Yemen.
TLDR
Evidence of usefulness of the training intervention on the national guidelines for malaria treatment in Yemen is provided and the involvement of private health-care providers in reporting procedures will promote the rational prescription and availability of anti-malaria drugs. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 72 REFERENCES
Artesunate versus quinine for treating severe malaria.
TLDR
This review did not identify sufficient data to make firm conclusions about the treatment of children or the effectiveness of intramuscular artesunate, the drug of choice for adults with severe malaria, particularly if acquired in Asia. Expand
Artesunate versus quinine for treating severe malaria.
TLDR
The evidence clearly supports the superiority of parenteral artesunate over quinine for the treatment of severe malaria in both adults and children and in different regions of the world. Expand
Artemisinin drugs: novel antimalarial agents
  • R. Price
  • Medicine
  • Expert opinion on investigational drugs
  • 2000
TLDR
The use of rectal preparations of artesunate and artemisinin at the rural health level will facilitate early initiation of the treatment of falciparum malaria and this may reduce the proportion of patients progressing to severe disease. Expand
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial
TLDR
Artesunate should become the treatment of choice for severe falciparum malaria in adults because it is more rapidly acting than intravenous quinine in terms of parasite clearance and is simpler to administer. Expand
The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria
TLDR
The large inter-individual variability in DHA Cmax and AUC in patients with potentially lethal, severe malaria, suggests that 2.4 mg/kg should be the minimum daily dose in severe malaria. Expand
Oral Artesunate Dose-Response Relationship in Acute Falciparum Malaria
TLDR
The results imply that there is no reduction in PCTs with the use of single doses of artesunate higher than 2 mg/kg, and this therefore reflects the average lower limit of the maximally effective dose. Expand
Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Severe Falciparum Malaria
  • Timothy M. E. Davis, H. L. Phuong, +6 authors T. Q. Binh
  • Medicine, Biology
  • Antimicrobial Agents and Chemotherapy
  • 2001
TLDR
Since the pharmacokinetic parameters for both artesunate and dihydroartemisinin were similar regardless of whether injection or infusion was used, artes unate can be considered a prodrug that is converted stoichiometrically to dhydroartsinin, and conventional doses of artes Unate are safe and effective when given to patients with complications of falciparum malaria. Expand
Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malaria.
TLDR
Artemisinin suppositories are easy to administer, cheap, and very effective for treating children with severe malaria and in rural areas where medical facilities are lacking these drugs will allow antimalarial therapy to be instituted earlier in the course of the disease and may therefore save lives. Expand
Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria.
  • P. Newton, B. Angus, +7 authors N. White
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2003
TLDR
A randomized, open-label comparison of artesunate and quinine was conducted in 113 adults with clinically severe falciparum malaria in western Thailand, and it was found that artes unate is at least as effective in the treatment of adults with severe malaria. Expand
Artemisinin resistance in Plasmodium falciparum malaria.
TLDR
P. falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand, and resistance is characterized by slow parasite clearance in vivo without corresponding reductions on conventional in vitro susceptibility testing. Expand
...
1
2
3
4
5
...